Navigation Links
Pharmos Corporation Reports 2007 Fourth Quarter and Year-end Results
Date:2/28/2008

ble bowel syndrome (IBS). The Company expects to enroll approximately 480 IBS patients in the double- blind, randomized, placebo-controlled study, with data expected in mid-2009.

Net research and development expenses increased 41.7%, to $10.6 million in 2007 from $7.5 million in 2006. The higher percentage increase compared to the percentage increase in gross research and development is due to a 43.8% decrease in grant funding in 2007 compared to 2006, due to lower qualifying expenditures in 2007. General and administrative expenses decreased 26.5% to $6.7 million in 2007 compared to $9.1 million in 2006, primarily due to lower professional fees, investor relations expenses and insurance costs, and reflecting an aggressive cost-containment program initiated in 2007. Other income (expense), net decreased 44.4% to net other income of $1.0 million compared to net other income of $1.8 million in 2006 primarily due to a reduction in interest income.

The 2007 net loss was also favorably impacted by the above-mentioned 56% increase in income tax benefit to $1.0 million in 2007 compared to $0.6 million in 2006.

Cash and Short-term Investments

Cash and short-term investments were $11.2 million on December 31, 2007. Subsequent to the 2007 year-end, Pharmos raised $4.0 million in gross proceeds from a January 2008 initial closing of a private placement of 10% Convertible Debentures due November 2012. Under the terms of the offering, the Company may raise gross proceeds up to an aggregate of $8.0 million from the sale of Debentures in the placement (including the Debentures issued at the initial closing) and is putting forth efforts toward a second closing. Purchasers participating in the initial closing consisted of certain existing investors in the Company, namely Venrock Associates, New Enterprise Associates, Lloyd I. Miller, III and Robert Johnston.

Net Operating Loss Shareholder Notice

Under Internal Revenue Code Section 382 rules,
'/>"/>

SOURCE Pharmos Corporation
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6

Related medicine news :

1. Pharmos Restructures Operations in Israel
2. National Atlantic Holdings Corporation to Report Fourth Quarter and Year-End 2007 Earnings on March 17, 2008
3. Linkwell Corporations Skin Disinfectant Product Chosen for 2008 Beijing Olympic Games
4. Partners Center for Connected Health and EMC Corporation Launch New Web-Based Remote Monitoring Program to Help Employees Fight Hypertension
5. China Bionanometer Industries Corporation Announces New Products for China
6. Centene Corporation Unveils Winners of the 2008 Physician Summit Award
7. Dialysis Corporation of America Announces its Newest Center Opening in South Carolina
8. Harris Corporation Demonstrates Digital Signage(TM) Solutions for Dynamic, Rapid Communications within Healthcare Enterprises
9. Harris Corporation Unveils Broadcast-Style Multiviewers for Real-Time Multi- Screen Access to Medical Information
10. Harris Corporation Demonstrates Remote Digital Imagery Display and Manipulation for Pathology Applications
11. Cerner Corporation and Hill-Rom Partner to Unify Hospital Care Delivery
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/16/2009)... As a result of C3: Colorectal Cancer Coalition,s advocacy ... research program is included in the final Fiscal Year ... research program will research cancers, like colorectal cancer, that ... ovarian cancer research programs run by the U.S. Army ... $15 million in funding for this new cancer research ...
(Date:12/16/2009)... Institute announce the first comprehensive analyses of cancer genomes. ... the DNA of cancer cells which are acquired during ... and a lung cancer, reveal for the first time ... cancers. , Lung cancer causes around one million deaths ... The number of mutations found suggest that a typical ...
(Date:12/16/2009)... Cost-Effective Care , ... Washington, D.C. (Vocus) December 16, ... ways to rein in runaway costs while providing care to all ... the ongoing discussion includes how to ensure patients equal access to ... (MDs) or osteopathy (DOs). In both the House and Senate ...
(Date:12/16/2009)... through annual marketing campaign , ... ... 2010 Genetown™ Hotbed Campaign as its largest yearly ... sponsored by MassBio and showcases 37 Massachusetts companies ... each entity’s brand on an electronic and printed map ...
(Date:12/16/2009)... Inc., developers of the AcceleDent System , ... announced Alison Davies as its new Director of ... spent the last fourteen years of her professional ... nine years as a senior manager with ... ,, (Logo: http://www.newscom.com/cgi-bin/prnh/20091029/DA01250LOGO ) ,, ...
Breaking Medicine News(10 mins):Health News:House Creates New Cancer Research Program 2Health News:House Creates New Cancer Research Program 3Health News:Lung cancer and melanoma laid bare 2Health News:Lung cancer and melanoma laid bare 3Health News:Lung cancer and melanoma laid bare 4Health News:Lung cancer and melanoma laid bare 5Health News:Lung cancer and melanoma laid bare 6Health News:Coalition for Patients' Rights: Access to Broad Range of Health Care Providers Critical to Lowering Costs 2Health News:Coalition for Patients' Rights: Access to Broad Range of Health Care Providers Critical to Lowering Costs 3Health News:Coalition for Patients' Rights: Access to Broad Range of Health Care Providers Critical to Lowering Costs 4Health News:Coalition for Patients' Rights: Access to Broad Range of Health Care Providers Critical to Lowering Costs 5Health News:Thriving Bioscience Region Leaves Its Mark 2Health News:Top-performing Sales Manager Joins OrthoAccel Technologies, Inc. in the United Kingdom 2Health News:Top-performing Sales Manager Joins OrthoAccel Technologies, Inc. in the United Kingdom 3Health News:Top-performing Sales Manager Joins OrthoAccel Technologies, Inc. in the United Kingdom 4
... room, The Flag Company, Inc.,s new ,Feel Good, Light Lenses are ... during this trying economical time. , ... (PRWEB) March ... has gripped the nation, the Flag Company, Inc. recently launched ,Feel ...
... at the KK Women,s and Children,s Hospital (KKH) can now opt ... an anesthetic-free yet almost painless operation to treat uterine fibroids. ... ... at the KK Women,s and Children,s Hospital (KKH) can ...
... the first in a series of residential vacuum cleaner reviews conducted in ... ... Idaho (Vocus) March 3, 2009 -- Before spending hundreds of dollars on ... savvy shoppers turn to the Internet to research their choices. , , ...
... March 3 Based on its recent analysis ... Sullivan recognizes Aesku.Diagnostics with the 2008 European Frost ... consistent approach towards product development. It has anticipated ... offered versatile immunoassay systems, extended research capabilities as ...
... /PRNewswire/ -- ... a division of United Business Media Limited, has signed ... to provide an integrated medicine management system for two ... Data Solutions are already used in approximately 700 hospitals ...
... The southeast Pacific nation of Papua New Guinea, home ... Earth, has created its first national conservation area to ... than Singapore. , The decision by the Papua New ... the newly established YUS Conservation Area, results from more ...
Other Medicine News:Health News:The Flag Company, Inc. Releases 'Feel Good' Light Lenses to Help Counter Gloomy Economic Outlook 2Health News:The Flag Company, Inc. Releases 'Feel Good' Light Lenses to Help Counter Gloomy Economic Outlook 3Health News:Singapore Premier Women's Hospital Offers Contactless Surgery for Uterine Fibroids 2Health News:Singapore Premier Women's Hospital Offers Contactless Surgery for Uterine Fibroids 3Health News:Singapore Premier Women's Hospital Offers Contactless Surgery for Uterine Fibroids 4Health News:Shopping for a Vacuum Cleaner? Know What You're Buying! Internet Site and Rating System Can Help 2Health News:Shopping for a Vacuum Cleaner? Know What You're Buying! Internet Site and Rating System Can Help 3Health News:Frost & Sullivan Lauds Aesku.Diagnostics For Providing an Overall Analysis Platform For a Wide Range of Autoimmune Complications 2Health News:Frost & Sullivan Lauds Aesku.Diagnostics For Providing an Overall Analysis Platform For a Wide Range of Autoimmune Complications 3Health News:Frost & Sullivan Lauds Aesku.Diagnostics For Providing an Overall Analysis Platform For a Wide Range of Autoimmune Complications 4Health News:CMPMedica Signs an Agreement With MAIDIS for e-prescribing Solutions in Abu Dhabi (UAE) 2Health News:CMPMedica Signs an Agreement With MAIDIS for e-prescribing Solutions in Abu Dhabi (UAE) 3Health News:Papua New Guinea declares first national conservation area 2Health News:Papua New Guinea declares first national conservation area 3Health News:Papua New Guinea declares first national conservation area 4
(Date:12/16/2009)... Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: ... 2010 the U.S. Food and Drug Administration,s ... the New Drug Application (NDA) for pixantrone ... lymphoma (NHL). ODAC is an independent panel ... efficacy and safety of marketed and investigational ...
(Date:12/16/2009)... Today, a group of national medical societies ... 3590, the Patient Protection and Affordable Care Act, currently ... way towards a final vote in the coming days. ... to vote against a health care bill that is ... hand that our health care system needs reform - ...
(Date:12/16/2009)... , Dec. 16 MedSolutions ( ... management services, today commended two new studies highlighting ... scans and other diagnostic imaging tests. ,, ... proper diagnosis and treatment," said Gregg Allen, M.D., ... studies offer more compelling evidence that stricter quality ...
Breaking Medicine Technology:Cell Therapeutics Announces FDA's Oncologic Drugs Advisory Committee to Review Pixantrone for the Treatment of Relapsed/Refractory Aggressive Non-Hodgkin's Lymphoma, February 10, 2010 2Cell Therapeutics Announces FDA's Oncologic Drugs Advisory Committee to Review Pixantrone for the Treatment of Relapsed/Refractory Aggressive Non-Hodgkin's Lymphoma, February 10, 2010 3Cell Therapeutics Announces FDA's Oncologic Drugs Advisory Committee to Review Pixantrone for the Treatment of Relapsed/Refractory Aggressive Non-Hodgkin's Lymphoma, February 10, 2010 4Physician Groups Oppose Current Senate Health Care Reform Bill 2MedSolutions Applauds Renewed Focus on the Dangers of Radiation Exposure 2MedSolutions Applauds Renewed Focus on the Dangers of Radiation Exposure 3PARI LC Plus and PRONEB Ultra Used in Two Perforomist Studies on Improving COPD Therapies 4671 1PARI LC Plus and PRONEB Ultra Used in Two Perforomist Studies on Improving COPD Therapies 4671 2Pennsylvania Department of Health Workshops Will Help Businesses Prepare for Flu Pandemic 50436 1Pennsylvania Department of Health Workshops Will Help Businesses Prepare for Flu Pandemic 50436 2Spanish Government Selects Novavaxs VLP Technology for Comprehensive Flu Vaccine Solution in Spain 12852 1Spanish Government Selects Novavaxs VLP Technology for Comprehensive Flu Vaccine Solution in Spain 12852 2Spanish Government Selects Novavaxs VLP Technology for Comprehensive Flu Vaccine Solution in Spain 12852 3Spanish Government Selects Novavaxs VLP Technology for Comprehensive Flu Vaccine Solution in Spain 12852 4Spanish Government Selects Novavaxs VLP Technology for Comprehensive Flu Vaccine Solution in Spain 12852 5
For use with catalog #0454....
Determination of FDP in Plasma by Latex Agglutination, 60 tests.Microlatex particles coated with mouse monoclonal anti-human FDP antibodies....
Lupus Anticoagulant-Sensitive APTT Reagent.Cephalin with particulate activator (silica), freeze-dried....
Detection of Lupus Anticoagulants. Freeze-dried hexagonal phase phos-phatidylethanolamine; normal plasmawith heparin inhibitor; PTT-LS reagent of cephalin and particulate siliceous activator;all free...
Medicine Products: